CXCL13 and neoplasm: Focusing on ICI-responsive GCs, we found a substantial proportion of pre-treatment ISG-15+CD8+ T clonotypes in effector T-cell populations (CXCL13+CD8+ T, ZNF683+ Tem and GZMK+ Tem) of post-treatment EBV (+) tumours.